NSAID Use Selectively Increases the Risk of Non-Fatal Myocardial Infarction: A Systematic Review of Randomised Trials and Observational Studies
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Recent clinical trials and observational studies have reported increased coronary events associated with non steroidal anti-inflammatory drugs (NSAIDs). There appeared to be a disproportionate increase in non-fatal versus fatal events, however, numbers of fatal events in individual studies were too small, and event rates too low, to be meaningful. OBJECTIVES: We undertook a pooled analysis to investigate the effect of NSAIDs on myocardial infarction (MI) risk with the specific aim to differentiate non-fatal from fatal events. METHODS: We searched Pubmed (January, 1990 to March, 2010) for observational studies and randomised controlled trials that assessed the effect of NSAIDs (traditional or selective COX-2 inhibitors [coxibs]) on MI incidence separately for fatal and non-fatal events. Summary estimates of relative risk (RR) for non-fatal and fatal MIs were calculated with a random effects model. RESULTS: NSAID therapy carried a RR of 1.30 (95% CI, 1.20-1.41) for non-fatal MI with no effect on fatal MI (RR 1.02, 95% CI, 0.89-1.17) in six observational studies. Overall, the risk increase for non-fatal MI was 25% higher (95% CI, 11%-42%) than for fatal MI. The two studies that included only individuals with prior cardiovascular disease presented risk estimates for non-fatal MI on average 58% greater (95% CI, 26%-98%) than those for fatal MI. In nine randomised controlled trials, all investigating coxibs, the pooled RR estimate for non-fatal MI was 1.61 (95% CI, 1.04-2.50) and 0.86 (95% CI 0.51-1.47) for fatal MIs. CONCLUSIONS: NSAID use increases the risk of non-fatal MI with no substantial effect on fatal events. Such differential effects, with potentially distinct underlying pathology may provide insights into NSAID-induced coronary pathology. We studied the association between the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and the risk of myocardial infarction (MI), separating non-fatal from fatal events, summarizing the evidence from both observational studies and randomised controlled trials. An increased risk of non-fatal MI was clearly found in both types of studies while use of NSAID did not confer an increased risk of fatal MI. Our findings provide support for the concept that thrombi generated under NSAID treatment could be different from spontaneous thrombi.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, the treatments of endometriosis, such as hysterectomy or oophorectomy (20-24) and analgesics (25) may confer increased risk of CHD to women with endometriosis.”
From Endometriosis and Risk of Coronary Heart Disease (2016) · cites this paper as [25]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027 · cited 1×
“The first study to show an increased risk of MI with a coxib was the VIGOR trial [1], which was designed to compare the gastrointestinal safety of rofecoxib and naproxen in patients with rheumatoid arthritis.”
BackgroundAltman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519 · cited 2×
“associated with selective COX-2 inhibitors (coxibs)[1–4], there is growing concern and evidence that NSAIDs predispose to”
BackgroundMethodThe Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
Kearney, P. M., Baigent, C., Godwin, J., Halls, H., Emberson, J. R., & Patrono, C. (2006) · BMJ · doi:10.1136/bmj.332.7553.1302 · Cited by 1,445
Low-Dose Aspirin for the Prevention of Atherothrombosis
Patrono, C., García Rodríguez, L. A., Landolfi, R., & Baigent, C. (2005) · New England Journal of Medicine · doi:10.1056/nejmra052717 · Cited by 1,218 · cited 1×
“Randomised controlled trials with low dose aspirin have consistently shown a clear reduction in risk of non fatal MI and to a lesser extent fatal MI in high risk patients [21–25].”
BackgroundMcGettigan, P., & Henry, D. (2006) · JAMA · doi:10.1001/jama.296.13.jrv60011 · Cited by 1,096 · cited 1×
“Yet, when we analyzed the combined estimate (fatal and non-fatal MI) in our subset of studies, the results are similar to those reported in previous meta-analyses of observational studies [28,29] and RCTs [30].”
Result
Research works printed but not linked: 1
- García Rodríguez LA Cea Soriano L Martín-Merino E Johansson S 2009 Discontinuation of Low-Dose cetylsalicylic Acid Treatment for Secondary Prevention of Cardiovascular Outcomes is Associated With an Increased Risk of Myocardial Infarction. Circulation 120 S405
Cited by
Khanna, D., Fitzgerald, J. D., Khanna, P. P., Bae, S., Singh, M. K., Neogi, T., Pillinger, M. H., Merill, J., Lee, S., Prakash, S., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21772 · Cited by 1,536
“Conversely, in a recent study, the double contour sign was not universally 33% of subjects in an ultrasound survey of multiple joints in each subject) in patients with early gout not receiving ULT (66).”
Khanna, D., Khanna, P. P., Fitzgerald, J. D., Singh, M. K., Bae, S., Neogi, T., Pillinger, M. H., Merill, J., Lee, S., Prakash, S., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21773 · Cited by 728
“Assessment of modulation of cardiovascular event risks by colchicine prophylaxis or by NSAIDs (66) in patients with gout would be particularly informative.”
BackgroundMcGettigan, P., & Henry, D. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001098 · Cited by 571
“Meta-analyses of randomised data on adverse events, preferable in theory to observational data, may be constrained by small numbers of events [9–11,23,24].”
BackgroundMethodInfluentialEndometriosis and Risk of Coronary Heart Disease
Mu, F., Rich-Edwards, J., Rimm, E. B., Spiegelman, D., & Missmer, S. A. (2016) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.002224 · Cited by 235
“In addition, the treatments of endometriosis, such as hysterectomy or oophorectomy (20-24) and analgesics (25) may confer increased risk of CHD to women with endometriosis.”
Association Between Endometriosis and Hypercholesterolemia or Hypertension
Mu, F., Rich-Edwards, J., Rimm, E. B., Spiegelman, D., Forman, J. P., & Missmer, S. A. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.09056 · Cited by 180
“trials and observational studies showed that nonsteroidal antiinflammatory drugs use increased the risk of nonfatal myocardial infarction with no substantial effect on fatal events.(45) This finding may in part explain that the association between endometriosis and hypercholesterolemia/hypertension can be partially ac…”
ResultNon-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis
Gunter, B., Butler, K. A., Wallace, R. L., Smith, S. M., & Harirforoosh, S. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12484 · Cited by 150
Lichtenberger, L. M., Zhou, Y., Jayaraman, V., Doyen, J. R., O’Neil, R. G., Dial, E. J., Volk, D. E., Gorenstein, D. G., Boggara, M. B., & Krishnamoorti, R. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.04.002 · Cited by 141
Aggravation of Exercise-Induced Intestinal Injury by Ibuprofen in Athletes
VAN WIJCK, K., LENAERTS, K., VAN BIJNEN, A. A., BOONEN, B., VAN LOON, L. J. C., DEJONG, C. H. C., & BUURMAN, W. A. (2012) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e318265dd3d · Cited by 106
“Recent studies have demonstrated an increased risk of cardiovascular adverse events associated with the use of NSAIDs (7,13,17,22).”
BackgroundCOX Inhibition Profile and Molecular Docking Studies of Some 2-(Trimethoxyphenyl)-Thiazoles
Oniga, S. D., Pacureanu, L. M., Stoica, C. I., Palage, M., Craciun, A. M., Rusu, L., Crisan, L., & Araniciu, C. (2017) · Molecules · doi:10.3390/molecules22091507 · Cited by 86
“While some adverse reactions concerning gastrointestinal manifestations (gastritis, ulcer, bleeding) are well documented and established, others, like the cardiovascular risk, are still being assessed today [1,2].”
BackgroundAtherosclerosis in Systemic Lupus Erythematosus
Stojan, G., & Petri, M. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31829dd857 · Cited by 93
“Nonsteroidal anti-inflammatory drug (NSAID) treatment predisposes to nonfatal and fatal cardiovascular events.(65) Rofecoxib is associated with the highest risk of MI; ibuprofen with the highest risk of stroke; and diclofenac with the highest risk of cardiovascular death.”
BackgroundAtchison, J. W., Herndon, C. M., & Rusie, E. (2013) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2013.19.s9.1 · Cited by 92
de Abajo, F. J., Gil, M., García-Poza, P., Bryant, V., Oliva, B., Timoner, J., & García‐Rodríguez, L. A. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3617 · Cited by 75
Self-citationKirkby, N. S., Zaiss, A. K., Urquhart, P., Jiao, J., Austin, P. J., Al-Yamani, M., Lundberg, M. H., Mackenzie, L. S., Warner, T. D., Nicolaou, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069524 · Cited by 66
“It is now clear that both traditional NSAIDs and COX-2 selective inhibitors are also associated with a small but definite increase in the risk of atherothrombotic events in man [11], particularly myocardial infarction.”
BackgroundPharmacotherapy for chronic non-specific low back pain: current and future options
Koes, B. W., Backes, D., & Bindels, P. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1454430 · Cited by 62
Kirkby, N. S., Lundberg, M. H., Wright, W. R., Warner, T. D., Paul‐Clark, M. J., & Mitchell, J. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098165 · Cited by 67
“This particularly manifests as an increase in rates of myocardial infarction [1,7,8,9,10], which is consistent with data from animal models showing that COX-2 deletion or inhibition can produce a prothrombotic phenotype [11,12,13].”
ResultThe Challenges of Gout Management in the Elderly
Stamp, L. K., & Jordan, S. (2011) · Drugs & Aging · doi:10.2165/11592750-000000000-00000 · Cited by 53
Salvo, F., Antoniazzi, S., Duong, M., Molimard, M., Bazin, F., Fourrier‐Réglat, A., Pariente, A., & Moore, N. D. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.907792 · Cited by 55
Chang, Y., Liu, J., Hsu, Y., Tarng, D., & Hsu, C. (2015) · Medicine · doi:10.1097/md.0000000000001362 · Cited by 50
COX inhibitors: a patent review (2011 – 2014)
Consalvi, S., Biava, M., & Poce, G. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1090973 · Cited by 44
The Management of Chronic Pain in Important Patient Subgroups
Cherubino, P., Sarzi‐Puttini, P., Zuccaro, S. M., & Labianca, R. (2012) · Clinical Drug Investigation · doi:10.2165/11630060-000000000-00000 · Cited by 46
A retrospective multicenter study on long-term prevalence of chronic pain after cardiac surgery
Claudio, M., Faggiano, P. M., Cesare, G., Ambrosetti, M., & Temporelli, P. L. (2015) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000271 · Cited by 42
Fogh, K., Andersen, M. B., Bischoff‐Mikkelsen, M., Bause, R., Zutt, M., Schilling, S., Schmutz, J. ‐., Borbujo, J. M., Jimenez, J. A., Cartier, H., et al. (2012) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2012.00844.x · Cited by 35
Vessières, E., Guihot, A., Toutain, B., Maquigneau, M., Fassot, C., Loufrani, L., & Henrion, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068217 · Cited by 38
“Nevertheless, it should be noted that the use of COX-2 inhibitors is not recommended as these drugs possess deleterious side effects including higher risk of myocardial infaction [64].”
BackgroundAssessment of nonsteroidal anti-inflammatory drug-induced cardiotoxicity
Singh, B. K., Haque, S. E., & Pillai, K. K. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.856881 · Cited by 35
“However, CV thrombotic hazard among NSAIDs were different [9-14].”
BackgroundLima, A. O. D. L., Salamanca‐Fernández, E., Rey, E. J. A. D., Hoces, A. M., Vera, M. Á. G., & Bermúdez‐Tamayo, C. (2021) · Anales del Sistema Sanitario de Navarra · doi:10.23938/assn.0965 · Cited by 28
Bavry, A. A., Thomas, F., Allison, M., Johnson, K., Howard, B. V., Hlatky, M. A., Manson, J. E., & Limacher, M. C. (2014) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000800 · Cited by 27
Ou, S., Chen, Y., Chao, P.-W., Lee, Y.-J., Liu, C., Yeh, C., Chen, T., Chen, T.-W., Yang, W.-C., & Li, S. (2013) · Kidney International · doi:10.1038/ki.2013.79 · Cited by 24
Patrício, J. P. H., Barbosa, J., Ramos, R. M. M., Antunes, N. F. P., & de Melo, P. C. S. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0052-6 · Cited by 28
“coxibs [56].”
Ragab, F. A.-F., Mohammed, E. I., Jaleel, G. A. A., Selim, A. A. M. A., & Nissan, Y. M. (2020) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c20-00193 · Cited by 21
Araniciu, C., Pârvu, A. E., Palage, M., Oniga, S. D., Benedec, D., Oniga, I., & Oniga, O. (2014) · Molecules · doi:10.3390/molecules19079240 · Cited by 18
“Adverse reactions are numerous and frequent, stretching from gastro-intestinal problems to cardiovascular and renal events [1–4].”
BackgroundInsights from pharmacovigilance and pharmacodynamics on cardiovascular safety signals of NSAIDs
Liang, S., Wang, X., & Zhu, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1455212 · Cited by 18
Sudden cardiac death in football
Bohm, P., Kästner, A., & Meyer, T. (2013) · Journal of Sports Sciences · doi:10.1080/02640414.2013.796064 · Cited by 18
Grimaldi‐Bensouda, L., Rossignol, M., Danchin, N., Steg, P. G., Bessede, G., Ovize, M., Cottin, Y., Autret‐Leca, E., Bénichou, J., Abenhaim, L., et al. (2011) · Heart · doi:10.1136/hrt.2011.222448 · Cited by 15
Cardio‐Metabolic Risk Profile of Women With Endometriosis: A Population‐Based Study
Naz, M. S. G., Noroozzadeh, M., Ardebili, S. N., Mousavi, M. A., Azizi, F., & Tehrani, F. R. (2024) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70008 · Cited by 17
“Endometriosis (EM) is a common debilitating clinical condition among women that affects about 18% of them [1].”
BackgroundDevelopmental Pathways in CAVD
Elaine, E., & Katherine, E. (2013) · InTech eBooks · doi:10.5772/54356 · Cited by 8
“How‐ ever, one caveat is that COX2 inhibitor therapy can be associated with some rare but signifi‐ cant adverse cardiovascular events such as myocardial infarction and stroke [252, 253].”
BackgroundSerrano, J. L. S., Tenías, J. M., Arias, Á., Carreras, M. I. M., & Gámez, J. C. V. (2015) · Revista Española de Salud Pública · doi:10.4321/s1135-57272015000600008 · Cited by 6
Synthesis of PVA capped naproxen conjugated MgO nanoparticles and its bioactivity screening
Razzaq, A., Naz, S. S., Qureshi, I., Rehman, F. U., & Qaisar, S. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103429 · Cited by 6
Atherosclerosis and Cardiovascular Disease in Rheumatoid Arthritis
Frostegård, J. (2012) · The Journal of Rheumatology · doi:10.3899/jrheum.121153 · Cited by 5
Tripathi, A., Arsha, S., Thapa, A., Thapa, S., Chand, S., Frishman, W. H., & Aronow, W. S. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000759 · Cited by 4
Coronary Artery Disease: Regulation of Coronary Blood Flow
Bache, R. J. (2015) · Cardiovascular medicine · doi:10.1007/978-1-4471-2828-1_4 · Cited by 5
Asociación entre el síndrome coronario agudo y el consumo de antiinflamatorios no esteroideos
Serrano, J. L. S., Tenías, J. M., Fernández, M., López, L. J., Serrano, A. P., & Hernández, M. Á. C. (2015) · Ars Pharmaceutica (Internet) · doi:10.4321/s2340-98942015000100001 · Cited by 3
DRUG SURVEILLANCE OF CARDIOVASCULAR RISKS DUE TO NON STEROID ANTI INFLAMMATORY COX-2 SELECTIVE
Machado‐Alba, J. E., Giraldo, C. G., & Ruiz, A. F. (2012) · Revista Investigaciones Andina · doi:10.33132/01248146.277 · Cited by 4
Sibutramine: balanced judgment or prejudice?
Coutinho, W. F., & James, W. P. T. (2011) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462011000200004 · Cited by 4
Anesthésie-réanimation en chirurgie cardiaque
Daccache, G., & Beaulieu, P. (2014) · Arnette eBooks · doi:10.3917/arne.fella.2014.01.0260 · Cited by 1
Nonsteroidal Anti‐inflammatory Drugs – Cyclooxygenase‐2 Inhibitors: Risks and Benefits
Chan, K. A. (2014) · Wiley eBooks · doi:10.1002/9781118820186.ch47
Garg, V. (2014) · UNM’s Digital Repository (University of New Mexico)
Gordon, L. A. (2015) · UKnowledge (University of Kentucky)
van Wijck, K. (2013) · Research Publications (Maastricht University) · doi:10.26481/dis.20130704kw
NSAIDs were associated with increased risk for mortality, regardless of time since first MI
Belknap, S. M. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-2-201301150-02010
Recomendaciones para el manejo del riesgo cardiovascular en pacientes con artritis reumatoide
Astete, C. A. G., Romero, C. R., Boteanu, A. L., Serrati, J. F. B., Quiñones, C. M., & Mendoza, A. C. Z. (2014) · Archivos de Medicina · Cited by 1
Treatment of acute gout in patients with coronary artery disease.
Chan, C. W., & Cheah, X. (2013) · Europe PMC (PubMed Central)
Напроксен: нова стратегія зниження серцево-судинного ризику нестероїдних протизапальних препаратів
Svyrydova, N. K. (2016) · INTERNATIONAL NEUROLOGICAL JOURNAL · doi:10.22141/2224-0713.5.83.2016.78478
Treatment of Lipid Metabolism Disturbances in Autoimmune Diseases
Ronda, N., & Meroni, P. L. (2017) · Technical report · doi:10.1016/b978-0-12-803997-7.00007-7
Risques cardiovasculaires et médicaments
Blacher, J. (2012) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(12)70348-6
Kramer, K. J., & Robert, R. C. (2015) · Wiley eBooks · doi:10.1002/9781119053231.ch23
Copsey, B. J. (2019) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-mprrex7vx
(2018) · Wiley eBooks · doi:10.1002/9781118829875.refs
Yarbrough, C., & Rosenbaum, D. A. (2013) · Athletic Training & Sports Health Care · doi:10.3928/19425864-20130709-12
Valdivieso, M. I. S. (2014) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/4862
Riesgo cardiovascular asociado al consumo de antiinflamatorios no esteroideos
Serrano, J. L. S. (2016) · Institutional Repository of the University of Granada (University of Granada)
Elkawafi, M., Elmansourya, M., Benamer, Z., Al-Majbri, S., Abdalmajeed, R. R., El-Naas, N. A., & Mumash, N. (2026) · Libyan Journal of Medical Research · doi:10.54361/ljmr.20.1.14
Metadata
- Authors
- García Rodríguez, L. A., González-Pérez, A., Bueno, H., & Hwa, J.
- Affiliations
- Hospital General Universitario Gregorio Marañón (ES)
- Yale University (US)
- Corresponding author
- Bueno, Héctor
- Hwa, John
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-02-08
- Volume
- 6
- Issue
- 2
- Pages
- e16780
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3035655
- OpenAlex
- W2082672105
- Semantic Scholar
- 98db6e8311b9d90c894b197f7ffdd324b155e51b
- Cited by
- 59
- References
- 37
- Citations by year
- 2024: 3 · 2022: 1 · 2021: 1 · 2020: 1 · 2018: 2 · 2017: 3 · 2016: 3 · 2015: 9 · 2014: 10 · 2013: 13 · 2012: 9
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- American Heart Association
- Pfizer
- Sanofi
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL074190)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- nonsteroidal anti-inflammatory drugs, nonfatal myocardial infarction, fatal myocardial infarction, COX-2 inhibitors, prior cardiovascular disease
- MeSH terms
- Anti-Inflammatory Agents, Non-Steroidal, Humans, Myocardial Infarction, Risk, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.